Atai Life Sciences Reports Positive Results from BPL-003 Phase 2a Study

LOS ANGELES- Atai Life Sciences has announced favorable outcomes from a Phase 2a open-label study evaluating BPL-003, an intranasal formulation of 5-MeO-DMT benzoate, in patients with moderate to severe alcohol use disorder (AUD). The study involved 12 participants who received a single dose of BPL-003 in conjunction with relapse prevention cognitive behavioral therapy. The findings revealed significant and sustained reductions in alcohol consumption over a 12-week period. Notably, 50% of the participants maintained complete abstinence throughout the study duration. BPL-003 was well-tolerated, with only mild to moderate adverse events reported, and no serious or severe adverse events occurred. Most patients were ready for discharge approximately two hours post-administration.

These results suggest that BPL-003, combined with cognitive behavioral therapy, may offer a rapid and durable therapeutic option for individuals with AUD. The brief treatment duration also indicates potential for efficient clinical application. Beckley Psytech, the developer of BPL-003, plans to explore further development opportunities for this compound in treating substance use disorders and intends to present additional clinical data in upcoming publications and conferences throughout 2025.